Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Corvus Pharma Com (CRVS)

Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Corvus Pharma Com 863 Mitten Road Suite102 BURLINGAME CA 94010 USA

www.corvuspharma.com P: 650-900-4520

Description:

Corvus Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on the development and commercialization of immuno-oncology therapies to harness the immune system to attack cancer cells. Its products include CPI-444, Adenosine production inhibitor, Adenosine A2B antagonist and Interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. Corvus Pharmaceuticals, Inc. is based in Burlingame, California.

Key Statistics

Overview:

Market Capitalization, $K 70,616
Enterprise Value, $K 57,996
Shares Outstanding, K 49,039
Annual Sales, $ 0 K
Annual Net Income, $ -27,030 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -6,650 K
EBIT, $ -23,400 K
EBITDA, $ -24,140 K
60-Month Beta 1.03
% of Insider Shareholders 31.30%
% of Institutional Shareholders 46.64%
Float, K 33,690
% Float 68.70%
Short Volume Ratio 0.61

Growth:

1-Year Return 44.34%
3-Year Return -48.94%
5-Year Return -64.53%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 68.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.14 on 03/19/24
Latest Earnings Date 05/13/24
Earnings Per Share ttm -0.57
EPS Growth vs. Prev Qtr -16.67%
EPS Growth vs. Prev Year 33.33%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CRVS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -59.63%
Return-on-Assets % -50.58%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.79
Book Value/Share 0.79
Interest Coverage -2.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar